NCT00570934

Brief Summary

2000 international units (IU) vitamin D, 1 gram (gm) calcium, or both given to children with Juvenile Rheumatoid Arthritis (JRA) may increase percent true calcium absorption, bone mineral turnover and/or bone mineralization.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Mar 1995

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 1995

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2002

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2002

Completed
5.8 years until next milestone

First Submitted

Initial submission to the registry

December 7, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 11, 2007

Completed
Last Updated

October 10, 2016

Status Verified

October 1, 2016

Enrollment Period

6.9 years

First QC Date

December 7, 2007

Last Update Submit

October 7, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percent true calcium absorption

    After 6 months of treatment

Secondary Outcomes (1)

  • Bone Mineralization by Dual Energy x-ray absorption

    After 6 months treatment plus 3 month washout

Study Arms (4)

Placebo

EXPERIMENTAL

order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol

Dietary Supplement: CholecalciferolDietary Supplement: CalciumDietary Supplement: Calcium and cholecalciferolDrug: Placebo

Calcium

EXPERIMENTAL

order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol

Dietary Supplement: CholecalciferolDietary Supplement: CalciumDietary Supplement: Calcium and cholecalciferolDrug: Placebo

Cholecalciferol

EXPERIMENTAL

order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium

Dietary Supplement: CholecalciferolDietary Supplement: CalciumDietary Supplement: Calcium and cholecalciferolDrug: Placebo

Calcium and cholecalciferol

EXPERIMENTAL

order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo

Dietary Supplement: CholecalciferolDietary Supplement: CalciumDietary Supplement: Calcium and cholecalciferolDrug: Placebo

Interventions

CholecalciferolDIETARY_SUPPLEMENT

2000IU Cholecalciferol P.O. Q.D.

CalciumCalcium and cholecalciferolCholecalciferolPlacebo
CalciumDIETARY_SUPPLEMENT

1 gm calcium as calcium carbonate

CalciumCalcium and cholecalciferolCholecalciferolPlacebo
Calcium and cholecalciferolDIETARY_SUPPLEMENT

2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months

CalciumCalcium and cholecalciferolCholecalciferolPlacebo

Placebo

CalciumCalcium and cholecalciferolCholecalciferolPlacebo

Eligibility Criteria

Age3 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Juvenile Rheumatoid arthritis

You may not qualify if:

  • Steroid use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Missouri Hospitals and clinics

Columbia, Missouri, 65203, United States

Location

Related Publications (1)

  • Hillman LS, Cassidy JT, Chanetsa F, Hewett JE, Higgins BJ, Robertson JD. Percent true calcium absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with vitamin D3 and calcium. Arthritis Rheum. 2008 Oct;58(10):3255-63. doi: 10.1002/art.23809.

MeSH Terms

Conditions

Arthritis, Juvenile

Interventions

CholecalciferolCalcium

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipidsMetals, Alkaline EarthElementsInorganic ChemicalsMetalsBlood Coagulation FactorsBiological Factors

Study Officials

  • Laura S Hillman, MD

    University of Missouri-Columbia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 7, 2007

First Posted

December 11, 2007

Study Start

March 1, 1995

Primary Completion

February 1, 2002

Study Completion

February 1, 2002

Last Updated

October 10, 2016

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share

Locations